Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.
New FDA regulatory pathways enable personalized gene-editing therapies customized to individual patients' genetic mutations.
This paper discusses how the FDA's new regulatory framework for plausible mechanism treatments enables development of personalized gene editing therapies for rare diseases. It describes a platform approach using prime editing that could be customized for individual patients' mutations.
What the study was
- Study design
- Perspective/review
- Population
- Rare disease patients eligible for gene editing
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- American Journal of Human Genetics
Why it surfaced
Highly novel — FDA regulatory pathway + prime editing for rare diseases, co-authored by David Liu and Kiran Musunuru. Published in AJHG. Perspective format limits design quality score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.